Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.

Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H, Minaga K, Kamata K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Enoki E, Inoue H, Matsumura I, Kudo M.

Intern Med. 2019 Jul 15;58(14):2029-2033. doi: 10.2169/internalmedicine.2495-18. Epub 2019 Apr 17.

2.

Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease.

Kono M, Komeda Y, Sakurai T, Okamoto A, Minaga K, Kamata K, Hagiwara S, Inoue H, Enoki E, Matsumura I, Watanabe T, Kudo M.

J Crohns Colitis. 2018 Mar 28;12(4):499-502. doi: 10.1093/ecco-jcc/jjx170.

PMID:
29253109
3.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.

Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

PMID:
27149138
4.

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S.

Gut. 2014 Apr;63(4):567-77. doi: 10.1136/gutjnl-2012-302853. Epub 2013 Mar 6.

PMID:
23468464
5.

Large-vessel thrombosis in intestinal Behçet's disease complicated with myelodysplastic syndrome and trisomy 8.

Chen HC, Chiu YM.

World J Gastroenterol. 2012 Mar 14;18(10):1137-40. doi: 10.3748/wjg.v18.i10.1137.

6.
7.

Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome.

Kimura M, Tsuji Y, Iwai M, Inagaki M, Madian A, Yoshino T, Matsuura M, Nakase H.

Intest Res. 2015 Apr;13(2):166-9. doi: 10.5217/ir.2015.13.2.166. Epub 2015 Apr 27.

8.

Enterocutaneous fistula in severely active Crohn's disease: preoperative anti-TNF alpha treatment to limit bowel resection-report of a case.

Wilhelm P, Kirschniak A, Johannink J, Kaufmann S, Klag T, Wehkamp J, Falch C.

Int J Colorectal Dis. 2019 Feb;34(2):369-373. doi: 10.1007/s00384-018-3206-4. Epub 2018 Nov 29.

PMID:
30498853
9.

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

MacDonald JK, Nguyen TM, Khanna R, Timmer A.

Cochrane Database Syst Rev. 2016 Nov 25;11:CD007572. Review.

10.

Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.

Tanaka H, Shimizu N, Tougasaki E, Kawajiri C, Hashimoto S, Takeda Y, Sakai S, Takeuchi M, Ohwada C, Sakaida E, Takagi T, Nakaseko C.

Int J Hematol. 2013 Apr;97(4):520-4. doi: 10.1007/s12185-013-1316-x. Epub 2013 Mar 22.

PMID:
23519573
11.

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

Khanna R, Preiss JC, MacDonald JK, Timmer A.

Cochrane Database Syst Rev. 2015 May 5;(5):CD007572. doi: 10.1002/14651858.CD007572.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Nov 25;11:CD007572.

PMID:
25942580
12.

Ustekinumab (Stelara) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.

13.
14.

Treatment of Crohn's disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review.

Hu C, Lv L, Liu D, Huo J.

Clin J Gastroenterol. 2014 Aug;7(4):299-304. doi: 10.1007/s12328-014-0496-0. Epub 2014 May 22. Review.

15.

Behçet's disease associated with myelodysplastic syndrome with elevated levels of inflammatory cytokines.

Hasegawa H, Iwamasa K, Hatta N, Fujita S.

Mod Rheumatol. 2003 Dec;13(4):350-5. doi: 10.3109/s10165-003-0245-6.

PMID:
24387258
16.

Clinical utility of ustekinumab in Crohn's disease.

Kotze PG, Ma C, Almutairdi A, Panaccione R.

J Inflamm Res. 2018 Feb 8;11:35-47. doi: 10.2147/JIR.S157358. eCollection 2018. Review.

17.

Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review.

Wesner N, Drevon L, Guedon A, Fraison JB, Terrier B, Trad S, Kahn JE, Aouba A, Gillard J, Ponsoye M, Hanslik T, Gourguechon C, Liozon E, Laribi K, Rossignol J, Hermine O, Seksik P, Adès L, Carrat F, Fenaux P, Mekinian A, Fain O; On behalf GFM and MINHEMON (French Network of dysimmune disorders associated with hemopathies).

Leuk Lymphoma. 2019 Jul;60(7):1782-1788. doi: 10.1080/10428194.2018.1542152. Epub 2018 Nov 20.

PMID:
30457024
18.

Concurrent inflammatory bowel disease and myelodysplastic syndromes.

Harewood GC, Loftus EV Jr, Tefferi A, Tremaine WJ, Sandborn WJ.

Inflamm Bowel Dis. 1999 May;5(2):98-103.

PMID:
10338378
19.

Biologic drugs for inflammatory bowel disease.

Yanai S, Matsumoto T.

Nihon Rinsho. 2017 Mar;75(3):403-407. English, Japanese.

PMID:
30566782
20.

Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.

Wong U, Cross RK.

Expert Opin Investig Drugs. 2019 May;28(5):473-479. doi: 10.1080/13543784.2019.1597053. Epub 2019 Mar 26. Review.

PMID:
30884245

Supplemental Content

Support Center